Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis
Marion T. Turnbull, Jason Siegel, Tara Becker, Alana Stephens, A. Sebastian López‐Chiriboga, William D. Freeman
Abstract
Introduction: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an increasingly recognized form of immune-mediated encephalitis. Here we present a case that represents the shortest hospitalization-to-bortezomib treatment timeline (42 days), and we believe that this is reflected in the patient's outcome with complete independence within a short timeframe.
Topics & Concepts
BortezomibMedicineEncephalitisRituximabAnti-NMDA receptor encephalitisNMDA receptorInternal medicinePediatricsOncologyImmunologyLymphomaReceptorVirusMultiple myelomaAutoimmune Neurological Disorders and TreatmentsPeripheral Neuropathies and DisordersGenetics and Neurodevelopmental Disorders